A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.
In one of the standout deals of the year so far, Roche entered into a $5.3 billion collaboration and license agreement with peptide therapeutics company Zealand Pharma to co-develop and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback